Literature DB >> 16148104

Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes.

Julian Schulze zur Wiesch1, Georg M Lauer, Cheryl L Day, Arthur Y Kim, Kei Ouchi, Jared E Duncan, Alysse G Wurcel, Joerg Timm, Andrea M Jones, Bianca Mothe, Todd M Allen, Barbara McGovern, Lia Lewis-Ximenez, John Sidney, Alessandro Sette, Raymond T Chung, Bruce D Walker.   

Abstract

A vigorous hepatitis C virus (HCV)-specific Th cell response is regarded as essential to the immunological control of HCV viremia. The aim of this study was to comprehensively define the breadth and specificity of dominant HCV-specific CD4(+) T cell epitopes in large cohorts of subjects with chronic and spontaneously resolved HCV viremia. Following in vitro stimulation of PBMC, HCV-specific cell cultures from each subject were screened with an overlapping panel of synthetic 20-mer peptides spanning the entire HCV polyprotein. Of 22 subjects who spontaneously controlled HCV viremia, all recognized at least one of a group of six epitopes situated within the nonstructural (NS) proteins NS3, NS4, and NS5, each of which was detected by >30% of subjects, but most subjects recognized additional, more heterogeneous specificities. In contrast, none of the most frequently targeted epitopes was detected by >5% of persons with chronic infection. The most frequently recognized peptides showed promiscuous binding to multiple HLA-DR molecules in in vitro binding assays and were restricted by different HLA-DR molecules in functional assays in different persons. These data demonstrate that predominant CD4(+) T cell epitopes in persons with resolved HCV infection are preferentially located in the nonstructural proteins and are immunogenic in the context of multiple class II molecules. This comprehensive characterization of CD4(+) T cell epitopes in resolved HCV infection provides important information to facilitate studies of immunopathogenesis and HCV vaccine design and evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148104     DOI: 10.4049/jimmunol.175.6.3603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Three-dimensional structure determines the pattern of CD4+ T-cell epitope dominance in influenza virus hemagglutinin.

Authors:  Samuel J Landry
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

2.  An asymmetric model of heterozygote advantage at major histocompatibility complex genes: degenerate pathogen recognition and intersection advantage.

Authors:  Rick J Stoffels; Hamish G Spencer
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

3.  Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.

Authors:  Julian Schulze Zur Wiesch; Adriana Thomssen; Philip Hartjen; Ilona Tóth; Clara Lehmann; Dirk Meyer-Olson; Kristina Colberg; Sebastian Frerk; Dalia Babikir; Stefan Schmiedel; Olaf Degen; Stefan Mauss; Jürgen Rockstroh; Schlomo Staszewski; Pavel Khaykin; Alexander Strasak; Ansgar W Lohse; Gerd Fätkenheuer; Joachim Hauber; Jan van Lunzen
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

6.  A population response analysis approach to assign class II HLA-epitope restrictions.

Authors:  Sinu Paul; Myles B C Dillon; Cecilia S Lindestam Arlehamn; Huang Huang; Mark M Davis; Denise M McKinney; Thomas Jens Scriba; John Sidney; Bjoern Peters; Alessandro Sette
Journal:  J Immunol       Date:  2015-05-06       Impact factor: 5.422

7.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

8.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

9.  Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.

Authors:  Christian Drouin; Stéphanie Lamarche; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  J Clin Virol       Date:  2009-12-01       Impact factor: 3.168

Review 10.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.